Back to Browse Journals » Blood and Lymphatic Cancer: Targets and Therapy » Volume 1

mTOR inhibitor in the treatment of Hodgkin’s lymphoma: a case report

Authors Ibeas P, Cantos B, Provencio M.

Published 8 November 2011 Volume 2011:1 Pages 19—22


Review by Single-blind

Peer reviewer comments 3

Patricia Ibeas, Blanca Cantos, Mariano Provencio
Clinical Oncology Department, Hospital Puerta de Hierro Majadahonda, Madrid, Spain

Abstract: Hodgkin’s disease is curable in 90% of the cases diagnosed in early stages (I and II) and in 70% of all patients who suffer from the disease. Refractory disease occurs in 10%–15% of cases and is still a clinical challenge. Its treatment is based on intensive chemotherapy regimens with transplantation, but there are patients who relapse after transplantation who have a poor prognosis. At this point in time, there is a lack of effective treatment options with proven efficacy and there is a real need to investigate new treatment drugs with different mechanisms of action. A persistent activation of mTOR signaling has been identified in leukemia, Hodgkin’s and non-Hodgkin’s lymphoma, and multiple myeloma. Everolimus, an mTOR kinase inhibitor, is being used as an option in these cases with encouraging results. Here, the authors report their experience with a patient treated with everolimus.

Keywords: everolimus, positron emission tomography, chemotherapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

A family-oriented treatment program for youths with ketamine abuse and their caregivers: a pilot study in Taiwan

Wang LJ, Lu SF, Chou WJ, Chong MY, Wang YH, Hsieh YL, Lee YH, Chen C

Neuropsychiatric Disease and Treatment 2015, 11:1921-1927

Published Date: 31 July 2015

Ultrasmall cationic superparamagnetic iron oxide nanoparticles as nontoxic and efficient MRI contrast agent and magnetic-targeting tool

Uchiyama MK, Toma SH, Rodrigues SF, Shimada AL, Loiola RA, Cervantes Rodríguez HJ, Oliveira PV, Luz MS, Rabbani SR, Toma HE, Poliselli Farsky SH, Araki K

International Journal of Nanomedicine 2015, 10:4731-4746

Published Date: 28 July 2015

Cu2+-RGDFRGDS: exploring the mechanism and high efficacy of the nanoparticle in antithrombotic therapy

Wu J, Wang Y, Wang Y, Zhao M, Zhang X, Gui L, Zhao S, Zhu H, Zhao J, Peng S

International Journal of Nanomedicine 2015, 10:2925-2938

Published Date: 15 April 2015

Systemic cytokine signaling via IL-17 in smokers with obstructive pulmonary disease: a link to bacterial colonization?

Andelid K, Tengvall S, Andersson A, Levänen B, Christenson K, Jirholt P, Åhrén C, Qvarfordt I, Ekberg-Jansson A, Lindén A

International Journal of Chronic Obstructive Pulmonary Disease 2015, 10:689-702

Published Date: 27 March 2015

Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies

Gopalakrishnan S, Tan D

Blood and Lymphatic Cancer: Targets and Therapy 2013, 3:19-24

Published Date: 18 April 2013

Erratum - Intracellular heavy metal nanoparticle storage

Iannitti T, Capone S, Gatti A, et al

International Journal of Nanomedicine 2011, 6:239-240

Published Date: 26 January 2011

Current and developing therapeutic agents in the treatment of Chagas disease

Werner Apt

Drug Design, Development and Therapy 2010, 4:243-253

Published Date: 17 September 2010

Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole

Izchak Kohen, Paula E Lester, Sum Lam

Neuropsychiatric Disease and Treatment 2010, 6:47-58

Published Date: 2 March 2010